Vanda's gastric drug flops in late-stage test, crashing the biotech's stock
You may remember Vanda Pharmaceuticals from its brief feud with the FDA over a partial clinical hold on gastric drug tradipitant — a fight it would lose in court a couple years ago. Now, that same drug is in hot water after failing a pivotal test.
Tradipitant, an in-licensed drug from Eli Lilly being tested in gastroparesis, flopped a Phase III study looking to reduce nausea symptoms against placebo, the biotech said Friday.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.